Selection of bacterial strains useful in allergy treatment
Inventors
Versalovic, James • Mollstam, Bo • Ganesh, Bhanu Priya
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11135255-B2
Publication Date
2021-10-05
Expiration Date
Abstract
Bacterial strains useful in prophylaxis, inhibition and/or treatment of an allergy in a mammal are selected by screening bacterial strains for capability of producing diacylglycerol kinase (DagK). A bacterial strain which is capable of producing DagK is then selected for use in prophylaxis, inhibition and/or treatment of the allergy.
Core Innovation
The invention relates to allergy prophylaxis, inhibition, and treatment by screening lactic acid bacterial strains for diacylglycerol kinase (DagK) production. A selected DagK-producing lactic acid bacterial strain is used to suppress histamine H1 receptor (H1R) pro-inflammatory histamine signaling while permitting histamine H2 receptor (H2R) anti-inflammatory effects.
In certain embodiments, the DagK-producing lactic acid bacterial strain is capable of releasing DagK extracellularly. The selection excludes L. reuteri strain ATCC PTA-6475 and identifies L. reuteri strain DSM 32273 and L. reuteri strain ATCC PTA-4659 in particular embodiments.
The method may include administering an H1-antihistamine in combination with the DagK-producing lactic acid bacterial strain, including cetirizine, ebastine, fexofenadine, loratadine, and desloratadine. Supporting experimental examples describe qRT-PCR evidence of dagK mRNA expression in specific L. reuteri strains and LC-MS/MS/sequence evidence for secreted DagK.
Claims Coverage
The document includes one independent claim directed to treating or reducing the risk of developing a food allergy in a mammal using a DagK-producing lactic acid bacterial strain. The claim set is further refined by dependent claims specifying extracellular release of DagK, particular L. reuteri strains, exclusion of L. reuteri strain ATCC PTA-6475, and optional administration of an H1-antihistamine selected from named compounds.
Treating or reducing risk of food allergy in a mammal
A method of treating or reducing the risk of developing a food allergy in a mammal by administering a diacylglycerol kinase (DagK) producing lactic acid bacterial strain to a mammal in need thereof.
Extracellularly releasing DagK producing lactic acid bacteria
The DagK producing lactic acid bacterial strain is capable of releasing DagK extracellularly.
Excluding a specific L. reuteri strain
The DagK producing lactic acid bacterial strain is not L. reuteri strain ATCC PTA-6475.
Specific L. reuteri strain candidate
The lactic acid bacterial strain is L. reuteri strain DSM 32273.
Alternative specific L. reuteri strain candidate
The lactic acid bacterial strain is L. reuteri strain ATCC PTA-4659.
Combining with an H1-antihistamine
The method further includes administering an H1-antihistamine.
H1-antihistamine selected from named compounds
The H1 antihistamine is selected from cetirizine, ebastine, fexofenadine, loratadine, or desloratadine.
Overall, the claim set covers administration of a DagK-producing lactic acid bacterial strain that can release DagK extracellularly for treating or reducing the risk of food allergy in a mammal, with exclusion of L. reuteri strain ATCC PTA-6475 and optional refinements to particular L. reuteri strains and combination therapy using an H1-antihistamine.
Stated Advantages
Treating or reducing the risk of developing a food allergy in a mammal.
Documented Applications
Allergy prophylaxis, inhibition, and treatment for food allergy in a mammal, including reducing the risk of developing a food allergy.
Use of screened lactic acid bacterial strains producing DagK, including extracellular release, to suppress histamine H1 receptor pro-inflammatory signaling while permitting histamine H2 receptor anti-inflammatory effects.
Combination use with an H1-antihistamine, including cetirizine, ebastine, fexofenadine, loratadine, or desloratadine, as part of the allergy-related method.
Interested in licensing this patent?